Genentech reports fenebrutinib Phase III results for PPMS

​Genentech has reported new data from the Phase III FENtrepid trial of fenebrutinib, an investigational Bruton’s tyrosine kinase inhibitor, for treating PPMS.

The post Genentech reports fenebrutinib Phase III results for PPMS appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.